Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to ascertain whether treatment with lenalidomide or lenalidomide
in combination with gemcitabine induces modulation of immune effector functions and to
characterize the nature of immune functions.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Maria Liljefors
Collaborators:
Celgene Corporation Karolinska Institutet Karolinska University Hospital